Q1 2022 13F Holders as of 3/31/2022
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
130M
-
Number of holders
-
83
-
Total 13F shares, excl. options
-
49.8M
-
Shares change
-
+5.17M
-
Total reported value, excl. options
-
$1.2B
-
Value change
-
+$125M
-
Number of buys
-
45
-
Number of sells
-
-26
-
Price
-
$24.15
Significant Holders of Vaxcyte, Inc. - COMMON STOCK (PCVX) as of Q1 2022
93 filings reported holding PCVX - Vaxcyte, Inc. - COMMON STOCK as of Q1 2022.
Vaxcyte, Inc. - COMMON STOCK (PCVX) has 83 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 49.8M shares
of 130M outstanding shares and own 38.32% of the company stock.
Largest 10 shareholders include FMR LLC (8.38M shares), RA CAPITAL MANAGEMENT, L.P. (4.58M shares), JANUS HENDERSON GROUP PLC (4.33M shares), Abingworth LLP (4.17M shares), TPG GP A, LLC (4.06M shares), VANGUARD GROUP INC (3.63M shares), BlackRock Inc. (2.89M shares), Frazier Life Sciences Management, L.P. (2.31M shares), Medicxi Ventures Management (Jersey) Ltd (1.89M shares), and ORBIMED ADVISORS LLC (1.51M shares).
This table shows the top 83 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.